Geron Valuation Multiples

Geron Overview

About Geron

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Founded

1990

HQ

Employees

229

Website

geron.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $196M

EBITDA: ($59M)

EV

$892M

Valuation Multiples

Multiples.vc

Start free trial

Geron Financials

Geron reported last 12-month revenue of $196M and negative EBITDA of ($59M).

In the same LTM period, Geron generated $189M in gross profit, ($59M) in EBITDA losses, and had net loss of ($71M).

Geron P&L

In the most recent fiscal year, Geron reported revenue of $184M and EBITDA of ($50M).

Geron expects next 12-month revenue of XXX and NTM EBITDA of XXX

Geron Stock Performance

Geron has current market cap of $1B, and enterprise value of $892M.

Geron's stock price is $1.76.

Geron Valuation Multiples

Geron trades at 4.5x EV/Revenue multiple, and (15.2x) EV/EBITDA.

Geron Financial Valuation Multiples

As of April 11, 2026, Geron has market cap of $1B and EV of $892M.

Equity research analysts estimate Geron's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Geron has a P/E ratio of (15.9x).

Geron Margins & Growth Rates

Geron's revenue in the last 12 month grew by 31%.

Geron's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $1.0M for the same period.

Geron's rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Geron's rule of X is 50% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Geron Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Geron M&A Activity

Geron acquired XXX companies to date.

Last acquisition by Geron was on XXXXXXXX, XXXXX. Geron acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Geron Investment Activity

Geron invested in XXX companies to date.

Geron made its latest investment on XXXXXXXX, XXXXX. Geron invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).